University of Texas Texas AM Investment Management Co. Invests $4.93 Million in Aileron Therapeutics, Inc. (NASDAQ:ALRN)

University of Texas Texas AM Investment Management Co. acquired a new stake in Aileron Therapeutics, Inc. (NASDAQ:ALRN - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,777,827 shares of the company's stock, valued at approximately $4,925,000. Aileron Therapeutics accounts for approximately 1.0% of University of Texas Texas AM Investment Management Co.'s investment portfolio, making the stock its 20th biggest holding. University of Texas Texas AM Investment Management Co. owned about 8.22% of Aileron Therapeutics at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Warberg Asset Management LLC purchased a new position in Aileron Therapeutics in the second quarter valued at about $86,000. Texas Capital Bank Wealth Management Services Inc raised its position in Aileron Therapeutics by 65.9% in the first quarter. Texas Capital Bank Wealth Management Services Inc now owns 26,171 shares of the company's stock valued at $174,000 after purchasing an additional 10,398 shares during the period. Finally, Nantahala Capital Management LLC raised its position in Aileron Therapeutics by 82.1% in the second quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company's stock valued at $1,286,000 after purchasing an additional 209,367 shares during the period. 90.89% of the stock is owned by hedge funds and other institutional investors.

Aileron Therapeutics Stock Down 8.0 %

Shares of Aileron Therapeutics stock traded down $0.29 during trading hours on Wednesday, hitting $3.33. 20,485 shares of the company's stock traded hands, compared to its average volume of 74,056. The stock has a 50 day simple moving average of $2.60 and a 200-day simple moving average of $3.56. The company has a market cap of $71.98 million, a PE ratio of -1.06 and a beta of 2.33. Aileron Therapeutics, Inc. has a twelve month low of $1.01 and a twelve month high of $7.42.

Aileron Therapeutics (NASDAQ:ALRN - Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.20). As a group, equities research analysts predict that Aileron Therapeutics, Inc. will post -1.41 EPS for the current year.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).